Albendazole kinetics in patients with echinococcosis: delayed absorption and impaired elimination in cholestasis

Details

Serval ID
serval:BIB_4F35C269A826
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Albendazole kinetics in patients with echinococcosis: delayed absorption and impaired elimination in cholestasis
Journal
European Journal of Clinical Pharmacology
Author(s)
Cotting  J., Zeugin  T., Steiger  U., Reichen  J.
ISSN
0031-6970 (Print)
Publication state
Published
Issued date
1990
Volume
38
Number
6
Pages
605-8
Notes
Journal Article
Research Support, Non-U.S. Gov't
Abstract
The pharmacokinetics of albendazole and its main metabolite, albendazole sulphoxide, have been examined after giving a single oral dose of 200 mg albendazole to 19 patients with either Echinococcus multilocularis or E. granulosus, 5 of whom had significant extrahepatic obstruction due to the underlying disease. The AUC of albendazole sulphoxide was increased in the latter patients (mean 122 mumols.h.l-1 compared to 17 mumols.h.l-1 in the non-obstructed group). Obstructed patients had delayed absorption, ka averaging 0.39 compared to 1.41 h-1 in non-obstructed patients. The corresponding elimination rate constant, ke was also prolonged, averaging 0.041 and 0.13 h-1 in the two groups, respectively. Four patients were restudied after complete or partial resolution of the cholestasis. The pharmacokinetic parameters in them had returned towards values comparable to those in the non-obstructed patients.
Keywords
Adult Aged Albendazole/analogs & derivatives/metabolism/*pharmacokinetics Cholestasis/*metabolism Echinococcosis/*metabolism Female Half-Life Humans Intestinal Absorption Male Middle Aged
Pubmed
Web of science
Create date
24/01/2008 16:41
Last modification date
20/08/2019 14:04
Usage data